Hypoglycemia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This reports provides a data-driven overview of the current and future competitive landscape in Hypoglycemia Therapeutics.
• In 2024 and 2029, India is estimated to have the highest number of diagnosed incident cases of hypoglycemia, representing a large portion of global cases.
• Novo Nordisk’s GlucaGen (glucagon hypokit) and Eli Lilly’s Glucagon had been the primary marketed glucagons for decades.
• The hypoglycemia pipeline holds 16 molecules, with no assets in the pre-registration stage, three assets in Phase III development, and another four in
Phase II.
• Over the past decade, 217 clinical trials have been conducted in hypoglycemia. The year with the most studies initiated was 2019, with 32 trials, followed by 2018 with 30 trials.
• During the past 24 months, three strategic alliances and four mergers and acquisitions involving companies developing hypoglycemia assets have been completed.
Scope
GlobalData’s Hypoglycemia: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include –
• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Hypoglycemia Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hypoglycemia Therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Hypoglycemia reports